MARLBOROUGH,
Mass., Feb. 21, 2025 /PRNewswire/ -- Boston
Scientific Corporation (the "Company") (NYSE: BSX) today
announced that American Medical Systems Europe B.V. ("AMS Europe"),
its wholly owned finance subsidiary, has priced a public offering
of €850,000,000 aggregate principal amount of 3.000% notes due 2031
and €650,000,000 aggregate principal amount of 3.250% notes due
2034 (collectively, the "Notes"). The Notes will be fully and
unconditionally guaranteed by the Company. The offering is being
made pursuant to a registration statement filed with the U.S.
Securities and Exchange Commission.
The offering is expected to close on February 26, 2025, subject to customary closing
conditions. The Company intends to use the net proceeds from the
offering, together with cash on hand, to fund the repayment at
maturity of AMS Europe's 0.750% senior notes due March 8, 2025 and to pay accrued and unpaid
interest with respect to such notes, and for general corporate
purposes, which may include, among other things, short term
investments, reduction of short term debt, funding of working
capital and potential future acquisitions.
Nothing herein shall constitute an offer to sell or the
solicitation of an offer to buy the securities, nor shall there be
any sale of the securities in any state or jurisdiction in which
such offer, solicitation or sale would be unlawful prior to
qualification under the securities laws of any such state or
jurisdiction. The offering is being made by means of a prospectus
and related preliminary prospectus supplement only, copies of which
or information concerning this offering may be obtained by
contacting the joint book-running managers: Barclays Bank PLC,
toll-free at 1-888-603-5847; Citigroup Global Markets Europe AG,
toll-free at 1-800-831-9146; or Wells Fargo Securities Europe S.A.
toll-free at 1-800-645-3751.
About Boston Scientific
Boston Scientific transforms lives through innovative medical
technologies that improve the health of patients around the world.
As a global medical technology leader for more than 45 years, we
advance science for life by providing a broad range of
high-performance solutions that address unmet patient needs and
reduce the cost of health care. Our portfolio of devices and
therapies helps physicians diagnose and treat complex
cardiovascular, respiratory, digestive, oncological, neurological
and urological diseases and conditions. Learn more at
www.bostonscientific.com and connect on LinkedIn and X, formerly
Twitter.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933, as amended, and Section 21E of the Securities Exchange Act
of 1934, as amended. Forward-looking statements may be identified
by words like "anticipate," "expect," "project," "believe," "plan,"
"estimate," "intend" and similar words. These forward-looking
statements are based on our beliefs, assumptions and estimates
using information available to us at the time and are not intended
to be guarantees of future events or performance. These
forward-looking statements include, among other things, statements
regarding the proposed offering and intended use of proceeds. If
our underlying assumptions turn out to be incorrect, or if certain
risks or uncertainties materialize, actual results could vary
materially from the expectations and projections expressed or
implied by our forward-looking statements. These factors, in some
cases, have affected and in the future (together with other
factors) could affect our ability to implement our business
strategy and may cause actual results to differ materially from
those contemplated by the forward-looking statements expressed in
this press release. As a result, readers are cautioned not to place
undue reliance on any of our forward-looking statements.
Risks and uncertainties that may cause such
differences include, among other things: economic conditions,
including the impact of foreign currency fluctuations, future U.S.
and global political, competitive, reimbursement and regulatory
conditions; geopolitical events; manufacturing, distribution and
supply chain disruptions and cost increases; disruptions caused by
cybersecurity events; disruptions caused by public health
emergencies or extreme weather or other climate change-related
events; labor shortages and increases in labor costs; variations in
outcomes of ongoing and future clinical trials and market studies;
new product introductions and the market acceptance of those
products; market competition for our products; expected pricing
environment; expected procedural volumes; the closing and
integration of acquisitions; demographic trends; intellectual
property rights; litigation; financial market conditions; the
execution and effect of our restructuring program; the execution
and effect of our business strategy, including our cost-savings and
growth initiatives; our ability to achieve environmental, social
and governance goals; and future business decisions made by us and
our competitors. New risks and uncertainties may arise from time to
time and are difficult to predict. All of these factors are
difficult or impossible to predict accurately and many of them are
beyond our control. For a further list and description of these and
other important risks and uncertainties that may affect our future
operations, see Part I, Item 1A – Risk Factors in our most recent
Annual Report on Form 10-K filed with the Securities and Exchange
Commission, which we may update in Part II, Item 1A – Risk Factors
in Quarterly Reports on Form 10-Q we will file hereafter. We
disclaim any intention or obligation to publicly update or revise
any forward-looking statements to reflect any change in our
expectations or in events, conditions or circumstances on which
those expectations may be based, or that may affect the likelihood
that actual results will differ from those contained in the
forward-looking statements, except as required by law. This
cautionary statement is applicable to all forward-looking
statements contained in this press release.
CONTACTS:
Chanel Hastings
Media Relations
+1 (508) 382-0288
Chanel.Hastings@bsci.com
Jon Monson
Investor Relations
+1 (508) 683-5450
BSXInvestorRelations@bsci.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/boston-scientific-announces-pricing-of-1-5-billion-of-senior-notes-302382716.html
SOURCE Boston Scientific Corporation
